Protagonist Partners With JNJ To Compete With AbbVie's Skyrizi (PTGX)

Last Wednesday , Johnson & Johnson ( JNJ ) announced that the FDA had approved Icotyde, a once-daily oral peptide for the treatment of plaque psoriasis. This drug selectively blocks the interleukin-23 receptor (IL-23) and was a joint discovery withBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employm ...